Recommended Topic Related To:

Prezista

"Nov. 29, 2012 -- It's possible to end the worldwide AIDS epidemic, and a new U.S. plan could make this possibility a reality.

The plan, announced in a formal presentation today by outgoing Secretary of State Hillary Clinton, takes adv"...

Prezista

Prezista Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Prezista (darunavir) is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Prezista is not a cure for HIV or AIDS. It is a type of antiviral medication called a protease inhibitor. Common side effects include diarrhea, nausea, vomiting, heartburn, stomach pain, weakness, and headache. Since Prezista is always taken with other HIV medications, it may be difficult to tell whether it is causing certain side effects.

The recommended oral dose of Prezista is 800 mg (two 400 mg tablets or 8 mL of the oral suspension) taken with ritonavir 100 mg (one 100 mg tablet/capsule or 1.25 mL of a 80 mg/mL ritonavir oral solution) once daily and with food. Prezista may interact with buprenorphine, naloxone, methadone, risperidone, thioridazine, antibiotics, antifungals, antidepressants, beta-blockers, blood thinners, calcium channel blockers, cholesterol-lowering medicines, drugs that weaken the immune system, heart rhythm medications, insulin or oral diabetes medications, medicines to treat erectile dysfunction, other HIV/AIDS medicines, seizure medications, or steroids. Many other medicines can interact with Prezista. Tell your doctor all medications and supplements you use. During pregnancy, Prezista should be used only when prescribed. It is normal to prescribe certain HIV medicines for pregnant women with HIV. This has been shown to decrease the risk of giving HIV to the baby. Consult your doctor. It is unknown if this medication passes into breast milk. Because breast milk can transmit HIV, do not breastfeed.

Our Prezista (darunavir) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Prezista in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using darunavir and call your doctor at once if you have:

  • the first sign of any skin rash, no matter how mild;
  • signs of a new infection, such as fever or chills, cough, flu symptoms, easy bruising or bleeding;
  • increased sweating, tremors in your hands, anxiety, feeling irritable, sleep problems (insomnia);
  • diarrhea, unexplained weight loss, menstrual changes, impotence, loss of interest in sex;
  • swelling in your neck or throat (enlarged thyroid);
  • muscle weakness, tired feeling, joint or muscle pain, feeling short of breath;
  • weakness or prickly feeling in your fingers or toes;
  • severe lower back pain, loss of bladder or bowel control;
  • problems with walking, breathing, speech, swallowing, or eye movement;
  • severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
  • nausea, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision); or
  • severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common side effects may include:

  • mild nausea, vomiting, stomach pain;
  • headache;
  • mild skin rash; or
  • changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Prezista (Darunavir) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Prezista Overview - Patient Information: Side Effects

SIDE EFFECTS: Since darunavir is always taken with other HIV medications, it may be difficult to tell whether darunavir is causing certain side effects. However, darunavir is known to cause diarrhea, nausea, vomiting, heartburn, stomach pain, and headache. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Some people may experience worsening of a previous medical condition (such as an old infection) as their immune systems improve, or develop new conditions because their immune systems have become overactive. This reaction may occur at any time (soon after starting HIV treatment or many months later). Tell your doctor right away if you have any serious side effects, including: unexplained weight loss, persistent muscle aches/weakness, joint pain, numbness/tingling of the hands/feet/arms/legs, severe tiredness, vision changes, severe/persistent headaches, signs of infection (such as fever, chills, trouble breathing, cough, non-healing skin sores), signs of an overactive thyroid (such as irritability, nervousness, heat intolerance, fast/pounding/irregular heartbeat, bulging eyes, unusual growth in the neck/thyroid known as a goiter), signs of a certain nerve problem known as Guillain-Barre Syndrome (such as difficulty breathing/swallowing/moving your eyes, drooping face, paralysis, slurred speech).

Get medical help right away if any of these rare but serious side effects occur: symptoms of a heart attack (such as chest/jaw/left arm pain, shortness of breath, unusual sweating), easy bruising/bleeding.

This drug may rarely cause serious (possibly fatal) liver problems. Tell your doctor right away if you notice any of the following rare but very serious side effects: persistent nausea/vomiting, severe stomach/abdominal pain, dark urine, yellowing eyes/skin.

Changes in body fat may occur while you are taking this medication (such as increased fat in the upper back and stomach areas, decreased fat in the arms and legs). The cause and long-term effects of these changes are unknown. Discuss the risks and benefits of treatment with your doctor, as well as the possible use of exercise to reduce this side effect.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Darunavir can commonly cause a rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe reaction. Get medical help right away if you develop any rash, especially with symptoms such as fever, tiredness, muscle/joint pain, blisters, mouth sores, or red/swollen eyes.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Prezista (Darunavir)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Prezista FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The overall safety profile of PREZISTA/ritonavir 800/100 mg once daily and PREZISTA/ritonavir 600/100 mg twice daily is based on clinical trials and post-marketing data, and is consistent with the data presented below.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Due to the need for co-administration of PREZISTA with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions.

Clinical Trials Experience: Treatment-Na´ve Adults

Study TMC114-C211

The safety assessment is based on all safety data from the Phase 3 trial TMC114-C211 comparing PREZISTA/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day in 689 antiretroviral treatment-na´ve HIV-1-infected adult subjects. The total mean exposure for subjects in the PREZISTA/ritonavir 800/100 mg once daily arm and in the lopinavir/ritonavir 800/200 mg per day arm was 162.5 and 153.5 weeks, respectively.

The majority of the adverse drug reactions (ADRs) reported during treatment with PREZISTA/ritonavir 800/100 mg once daily were mild in severity. The most common clinical ADRs to PREZISTA/ritonavir 800/100 mg once daily (greater than or equal to 5%) of at least moderate intensity (greater than or equal to Grade 2) were diarrhea, headache, abdominal pain and rash. 2.3% of subjects in the PREZISTA/ritonavir arm discontinued treatment due to ADRs.

ADRs to PREZISTA/ritonavir 800/100 mg once daily of at least moderate intensity (greater than or equal to Grade 2) in antiretroviral treatment-na´ve HIV-1-infected adult subjects are presented in Table 7 and subsequent text below the table.

Table 7: Selected Clinical Adverse Drug Reactions to PREZISTA/ritonavir 800/100 mg Once Daily* of at Least Moderate Intensity ( ≥ Grade 2) Occurring in ≥ 2% of Antiretroviral Treatment-Na´ve HIV-1-Infected Adult Subjects

System Organ Class, Preferred Term, %  Randomized Study TMC114-C211 
PREZISTA/ritonavir 800/100 mg once daily + TDF/FTC
N = 343 
lopinavir/ritonavir 800/200 mg per day + TDF/FTC
N = 346 
Gastrointestinal Disorders 
  Abdominal pain  6% 6%
  Diarrhea  9% 16%
  Nausea  4% 4%
  Vomiting  2% 4%
General Disorders and Administration Site Conditions 
  Fatigue  < 1%  3%
Metabolism and Nutrition Disorders 
  Anorexia  2% < 1% 
Nervous System Disorders 
  Headache  7% 6%
Skin and Subcutaneous Tissue Disorders 
  Rash  6% 7%
N=total number of subjects per treatment group
TDF = tenofovir disoproxil fumarate
FTC = emtricitabine
* Excluding laboratory abnormalities reported as ADRs

Less Common Adverse Reactions

Treatment-emergent ADRs of at least moderate intensity (greater than or equal to Grade 2) occurring in less than 2% of antiretroviral treatment-na´ve subjects receiving PREZISTA/ritonavir 800/100 mg once daily are listed below by body system:

Gastrointestinal Disorders: acute pancreatitis, dyspepsia, flatulence

General Disorders and Administration Site Conditions: asthenia

Hepatobiliary Disorders: acute hepatitis (e.g., acute hepatitis, cytolytic hepatitis, hepatotoxicity)

Immune System Disorders: (drug) hypersensitivity, immune reconstitution syndrome

Metabolism and Nutrition Disorders: diabetes mellitus

Musculoskeletal and Connective Tissue Disorders: myalgia, osteonecrosis

Psychiatric Disorders: abnormal dreams

Skin and Subcutaneous Tissue Disorders: angioedema, pruritus, Stevens-Johnson Syndrome, urticaria

Laboratory abnormalities

Selected Grade 2 to 4 laboratory abnormalities that represent a worsening from baseline observed in antiretroviral treatment-na´ve adult subjects treated with PREZISTA/ritonavir 800/100 mg once daily are presented in Table 8.

Table 8: Grade 2 to 4 Laboratory Abnormalities Observed in Antiretroviral Treatment-Na´ve HIV-1Infected Adult Subjects*

Laboratory Parameter Preferred Term, %  Limit  Randomized Study TMC114-C211 
PREZISTA/ ritonavir 800/100 mg once daily + TDF/FTC  lopinavir/ ritonavir 800/200 mg per day + TDF/FTC 
Biochemistry 
Alanine Aminotransferase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  9% 9%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  3% 3%
  Grade 4  > 10.0 X ULN  < 1%  3%
Aspartate Aminotransferase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  7% 10%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  4% 2%
  Grade 4  > 10.0 X ULN  1% 3%
Alkaline Phosphatase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  1% 1%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  0% < 1% 
  Grade 4  > 10.0 X ULN  0% 0%
Hyperbilirubinemia 
  Grade 2  > 1.5 to ≤ 2.5 X ULN  < 1%  5%
  Grade 3  > 2.5 to ≤ 5.0 X ULN  < 1%  < 1% 
  Grade 4  > 5.0 X ULN  0% 0%
Triglycerides 
  Grade 2  5.65-8.48 mmol/L 500-750 mg/dL  3% 10%
  Grade 3   8.49-13.56 mmol/L 751-1200 mg/dL  2% 5%
  Grade 4  > 13.56 mmol/L > 1200 mg/dL  1% 1%
Total Cholesterol 
  Grade 2  6.20-7.77 mmol/L 240-300 mg/dL  23% 27%
  Grade 3  > 7.77 mmol/L > 300 mg/dL  1% 5%
Low-Density Lipoprotein Cholesterol 
  Grade 2  4.13-4.90 mmol/L 160-190 mg/dL  14% 12%
  Grade 3  ≥ 4.91 mmol/L ≥ 191 mg/dL  9% 6%
Elevated Glucose Levels 
  Grade 2  6.95-13.88 mmol/L 126-250 mg/dL  11% 10%
  Grade 3  13.89-27.75 mmol/L 251-500 mg/dL  1% < 1% 
  Grade 4  > 27.75 mmol/L > 500 mg/dL  0% 0%
Pancreatic Lipase 
  Grade 2  > 1.5 to ≤ 3.0 X ULN  3% 2%
  Grade 3  > 3.0 to ≤ 5.0 X ULN  < 1%  1%
  Grade 4  > 5.0 X ULN  0% < 1% 
Pancreatic Amylase 
  Grade 2  > 1.5 to ≤ 2.0 X ULN  5% 2%
  Grade 3  > 2.0 to ≤ 5.0 X ULN  5% 4%
  Grade 4  > 5.0 X ULN  0% < 1% 
N=total number of subjects per treatment group
TDF = tenofovir disoproxil fumarate
FTC = emtricitabine
* Grade 4 data not applicable in Division of AIDS grading scale.

Clinical Trials Experience: Treatment-Experienced Adults

Study TMC114-C214

The safety assessment is based on all safety data from the Phase 3 trial TMC114-C214 comparing PREZISTA/ritonavir 600/100 mg twice daily versus lopinavir/ritonavir 400/100 mg twice daily in 595 antiretroviral treatment-experienced HIV-1-infected adult subjects. The total mean exposure for subjects in the PREZISTA/ritonavir 600/100 mg twice daily arm and in the lopinavir/ritonavir 400/100 mg twice daily arm was 80.7 and 76.4 weeks, respectively.

The majority of the ADRs reported during treatment with PREZISTA/ritonavir 600/100 mg twice daily were mild in severity. The most common clinical ADRs to PREZISTA/ritonavir 600/100 mg twice daily (greater than or equal to 5%) of at least moderate intensity (greater than or equal to Grade 2) were diarrhea, nausea, rash, abdominal pain and vomiting. 4.7% of subjects in the PREZISTA/ritonavir arm discontinued treatment due to ADRs.

ADRs to PREZISTA/ritonavir 600/100 mg twice daily of at least moderate intensity (greater than or equal to Grade 2) in antiretroviral treatment-experienced HIV-1-infected adult subjects are presented in Table 9 and subsequent text below the table.

Table 9: Selected Clinical Adverse Drug Reactions to PREZISTA/ritonavir 600/100 mg Twice Daily* of at Least Moderate Intensity ( ≥ Grade 2) Occurring in ≥ 2% of Antiretroviral Treatment-Experienced HIV-1-Infected Adult Subjects

System Organ Class, Preferred Term, %  Randomized Study TMC114-C214 
PREZISTA/ ritonavir 600/100 mg twice daily + OBR
N = 298 
lopinavir/ ritonavir 400/100 mg twice daily + OBR
N = 297 
Gastrointestinal Disorders 
  Abdominal distension  2% < 1% 
  Abdominal pain  6% 3%
  Diarrhea  14% 20%
  Dyspepsia  2% 1%
  Nausea  7% 6%
  Vomiting  5% 3%
General Disorders and Administration Site Conditions 
  Asthenia  3% 1%
  Fatigue  2% 1%
Metabolism and Nutrition Disorders 
  Anorexia  2% 2%
  Diabetes mellitus  2% < 1% 
Nervous System Disorders 
  Headache  3% 3%
Skin and Subcutaneous Tissue Disorders 
  Rash  7% 3%
N=total number of subjects per treatment group
OBR = optimized background regimen
* Excluding laboratory abnormalities reported as ADRs

Less Common Adverse Reactions

Treatment-emergent ADRs of at least moderate intensity (greater than or equal to Grade 2) occurring in less than 2% of antiretroviral treatment-experienced subjects receiving PREZISTA/ritonavir 600/100 mg twice daily are listed below by body system:

Gastrointestinal Disorders: acute pancreatitis, flatulence

Musculoskeletal and Connective Tissue Disorders: myalgia

Psychiatric Disorders: abnormal dreams

Skin and Subcutaneous Tissue Disorders: pruritus, urticaria

Laboratory abnormalities

Selected Grade 2 to 4 laboratory abnormalities that represent a worsening from baseline observed in antiretroviral treatment-experienced adult subjects treated with PREZISTA/ritonavir 600/100 mg twice daily are presented in Table 10.

Table 10: Grade 2 to 4 Laboratory Abnormalities Observed in Antiretroviral Treatment-Experienced HIV-1-Infected Adult Subjects*

Laboratory Parameter Preferred Term, %  Limit  Randomized Study TMC114-C214 
PREZISTA/ ritonavir 600/100 mg twice daily + OBR  lopinavir/ ritonavir 400/100 mg twice daily + OBR 
Biochemistry 
Alanine Aminotransferase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  7% 5%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  2% 2%
  Grade 4  > 10.0 X ULN  1% 2%
Aspartate Aminotransferase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  6% 6%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  2% 2%
  Grade 4  > 10.0 X ULN  < 1%  2%
Alkaline Phosphatase 
  Grade 2  > 2.5 to ≤ 5.0 X ULN  < 1%  0%
  Grade 3  > 5.0 to ≤ 10.0 X ULN  < 1%  < 1% 
  Grade 4  > 10.0 X ULN  0% 0%
Hyperbilirubinemia 
  Grade 2  > 1.5 to ≤ 2.5 X ULN  < 1%  2%
  Grade 3  > 2.5 to ≤ 5.0 X ULN  < 1%  < 1% 
  Grade 4  > 5.0 X ULN  < 1%  0%
Triglycerides 
  Grade 2  5.65-8.48 mmol/L 500-750 mg/dL  10% 11%
  Grade 3  8.49-13.56 mmol/L 751-1200 mg/dL  7% 10%
  Grade 4  > 13.56 mmol/L > 1200 mg/dL  3% 6%
Total Cholesterol 
  Grade 2  6.20-7.77 mmol/L 240-300 mg/dL  25% 23%
  Grade 3  > 7.77 mmol/L > 300 mg/dL  10% 14%
Low-Density Lipoprotein Cholesterol 
  Grade 2  4.13-4.90 mmol/L 160-190 mg/dL  14% 14%
  Grade 3  ≥ 4.91 mmol/L ≥ 191 mg/dL  8% 9%
Elevated Glucose Levels 
  Grade 2  6.95-13.88 mmol/L 126-250 mg/dL  10% 11%
 Grade 3  13.89-27.75 mmol/L 251-500 mg/dL  1% < 1% 
  Grade 4 > 27.75 mmol/L > 500 mg/dL  < 1%  0%
Pancreatic Lipase 
  Grade 2  > 1.5 to ≤ 3.0 X ULN  3% 4%
  Grade 3  > 3.0 to ≤ 5.0 X ULN  2% < 1% 
  Grade 4   > 5.0 X ULN  < 1%  0%
Pancreatic Amylase 
  Grade 2  > 1.5 to ≤ 2.0 X ULN  6% 7%
  Grade 3  > 2.0 to ≤ 5.0 X ULN  7% 3%
  Grade 4  > 5.0 X ULN  0% 0%
N=total number of subjects per treatment group
OBR = optimized background regimen
* Grade 4 data not applicable in Division of AIDS grading scale

Serious ADRs

The following serious ADRs of at least moderate intensity (greater than or equal to Grade 2) occurred in the Phase 2b studies and Phase 3 studies with PREZISTA/ritonavir: abdominal pain, acute hepatitis, acute pancreatitis, anorexia, asthenia, diabetes mellitus, diarrhea, fatigue, headache, hepatic enzyme increased, hypercholesterolemia, hyperglycemia, hypertriglyceridemia, immune reconstitution syndrome, low density lipoprotein increased, nausea, pancreatic enzyme increased, rash, Stevens-Johnson Syndrome, and vomiting.

Patients Co-Infected With Hepatitis B And/Or Hepatitis C Virus

In subjects co-infected with hepatitis B or C virus receiving PREZISTA/ritonavir, the incidence of adverse events and clinical chemistry abnormalities was not higher than in subjects receiving PREZISTA/ritonavir who were not co-infected, except for increased hepatic enzymes [see WARNINGS AND PRECAUTIONS]. The pharmacokinetic exposure in co-infected subjects was comparable to that in subjects without co-infection.

Clinical Trials Experience: Pediatric Patients

PREZISTA/ritonavir has been studied in combination with other antiretroviral agents in 3 Phase II trials. TMC114C212, in which 80 antiretroviral treatment-experienced HIV-1-infected pediatric subjects 6 to less than 18 years of age and weighing at least 20 kg were included, TMC114-C228, in which 21 antiretroviral treatment-experienced HIV-1-infected pediatric subjects 3 to less than 6 years of age and weighing at least 10 kg were included, and TMC114-C230 in which 12 antiretroviral treatment-na´ve HIV-1 infected pediatric patients aged from 12 to less than 18 years and weighing at least 40 kg were included. The TMC114-C212 and C228 trials evaluated PREZISTA/ritonavir twice daily dosing and the TMC114-C230 trial evaluated PREZISTA/ritonavir once daily dosing [see Use In Specific Populations and Clinical Studies]. Frequency, type, and severity of ADRs in pediatric subjects were comparable to those observed in adults.

Study TMC114-C212

Clinical ADRs to PREZISTA/ritonavir (all grades, greater than or equal to 3%), were vomiting (13%), diarrhea (11%), abdominal pain (10%), headache (9%), rash (5%), nausea (4%) and fatigue (3%).

Grade 3 or 4 laboratory abnormalities were ALT increased (Grade 3: 3%; Grade 4: 1%), AST increased (Grade 3: 1%), pancreatic amylase increased (Grade 3: 4%, Grade 4: 1%), pancreatic lipase increased (Grade 3: 1%), total cholesterol increased (Grade 3: 1%), and LDL increased (Grade 3: 3%).

Study TMC114-C228

Clinical ADRs to PREZISTA/ritonavir (all grades, greater than or equal to 5%), were diarrhea (24%), vomiting (19%),rash (19%), abdominal pain (5%) and anorexia (5%).

There were no Grade 3 or 4 laboratory abnormalities considered as ADRs in this study.

Study TMC114-C230

Clinical ADRs to PREZISTA/ritonavir (all grades, greater than or equal to 3%), were vomiting (33%), nausea (25%), diarrhea (16.7%), abdominal pain (8.3%), decreased appetite (8.3%), pruritus (8.3%), and rash (8.3%).

There were no Grade 3 or 4 laboratory abnormalities considered as ADRs in this study.

Postmarketing Experience

The following events have been identified during post approval use of PREZISTA. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Redistribution of body fat has been reported.

Rarely, rhabdomyolysis (associated with co-administration with HMG-CoA reductase inhibitors and PREZISTA/ritonavir) has been reported.

In addition, toxic epidermal necrolysis,acute generalized exanthematous pustulosis and drug rash with eosinophilia and systemic symptoms have been reported rarely [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Prezista (Darunavir) »

A A A

Prezista - User Reviews

Prezista User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Prezista sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.